Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: cabazitaxel

« Back to Dashboard
Cabazitaxel is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and seventy-six patent family members in fifty-seven countries.

There are eleven drug master file entries for cabazitaxel. One supplier is listed for this compound.

Summary for Generic Name: cabazitaxel

Drug Master File Entries: see list11
Suppliers: see list1

Clinical Trials for: cabazitaxel

Cabazitaxel - PF Induction Chemotherapy
Status: Completed Condition: Squamous Cell Carcinoma of the Head and Neck

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Status: Recruiting Condition: Urothelium Transitional Cell Carcinoma

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Status: Active, not recruiting Condition: Hormone Refractory Prostate Cancer

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Status: Withdrawn Condition: Castrate-resistant Metastatic Prostate Cancer

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Active, not recruiting Condition: Urothelial Carcinoma

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Status: Terminated Condition: Prostate Cancer; Prostatic Neoplasms

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
Status: Recruiting Condition: Adenocarcinoma of Prostate; Progression of Prostate Cancer

A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
Status: Completed Condition: Urothelial Carcinoma

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Status: Terminated Condition: Neoplasms, Malignant

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes6,331,635<disabled>YY<disabled>
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes<disabled><disabled>
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes6,387,946<disabled><disabled>
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes7,241,907<disabled>Y<disabled>
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYes8,927,592<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: cabazitaxel

Country Document Number Publication Date
Finland953645Sep 27, 1995
Mexico2012005030Dec 05, 2012
South Korea20120093986Aug 23, 2012
Czech Republic287326Oct 11, 2000
European Patent Office0817780Jan 14, 1998
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn